Loading…
Loading…
Emmy Award-winning actress, entrepreneur and mom Keke Palmer partners with Sanofi to help educate families about protection against a serious respiratory syncytial virus (RSV) lung infection BEYFORTUS has been chosen by millions of parents to help protect their babies from serious RSV lung infection, a leading cause of hospitalization among babies under 1 year of age Campaign encourages parents to talk to their baby's doctor about helping protect their baby against serious RSV lung infection with BEYFORTUS, the #1 prescribed RSV immunization for babies MORRISTOWN, N.J., Sept. 8, 2026 /PRNewswire/ -- Sanofi is partnering with Emmy Award-winning actress, entrepreneur and mom Keke Palmer to help educate families about the importance of protection against serious RSV lung infection for babies.
Sanofi (NASDAQ: SNY - Get Free Report) has earned a consensus recommendation of "Hold" from the fifteen analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation, three have given a buy recommendation and two have assigned a
Sanofi's stock trades above key moving averages as Dupixent and new drugs drive growth, while pipeline setbacks and vaccine weakness weigh.
The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and Pfizer-BioNTech's updated COVID vaccines, the companies said on Thursday, after an advisory panel recommended that the shots should target the dominant XFG variant.
The FDA just approved the company's on-body injector for its blood cancer drug. Analysts see upside potential ahead for shares of the French pharmaceutical giant.
On August 10, Trump signed Executive Order 14420. But I believe the pressure on Sanofi stock from Trump's Gold Standard Childhood Vaccine Recommendations will be temporary. Sanofi is trading at a significant discount, with a non-GAAP P/E ratio [FWD] of 9.2x, 53.2% below the sector median.
Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.
Executed IP assignment brings a decade of technology, published research, and pharma-tested behavioral engagement capabilities into AimwellBio as the Company expands its scientific and medical advisory network MIAMI, FL / ACCESS Newswire / August 17, 2026 / AimwellBio (OTCID:AIMN) today announced the executed assignment of the Trustr intellectual property portfolio, a patented behavioral engagement system designed to measure real-world patient behavior and use precisely timed, data-driven interventions and rewards to support sustained adherence. The technology brings a substantial development history to the AimwellBio platform.